| Shared dysregulated pathways lead to Parkinson's disease and diabetes JA Santiago, JA Potashkin Trends in molecular medicine 19 (3), 176-186, 2013 | 248 | 2013 |
| The emerging role of nutrition in Parkinson's disease SE Seidl, JA Santiago, H Bilyk, JA Potashkin Frontiers in aging neuroscience 6, 74578, 2014 | 244 | 2014 |
| The impact of disease comorbidities in Alzheimer's disease JA Santiago, JA Potashkin Frontiers in aging neuroscience 13, 631770, 2021 | 146 | 2021 |
| System-based approaches to decode the molecular links in Parkinson's disease and diabetes JA Santiago, JA Potashkin Neurobiology of disease 72, 84-91, 2014 | 105 | 2014 |
| Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease JA Santiago, JA Potashkin Proceedings of the National Academy of Sciences 112 (7), 2257-2262, 2015 | 104 | 2015 |
| Biological and clinical implications of comorbidities in Parkinson’s disease JA Santiago, V Bottero, JA Potashkin Frontiers in aging neuroscience 9, 394, 2017 | 87 | 2017 |
| Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes JA Santiago, JA Potashkin PloS one 8 (12), e83940, 2013 | 86 | 2013 |
| Heterogeneous differentiation of human mesenchymal stem cells in response to extended culture in extracellular matrices JA Santiago, R Pogemiller, BM Ogle Tissue Engineering Part A 15 (12), 3911-3922, 2009 | 86 | 2009 |
| Dissecting the molecular mechanisms of neurodegenerative diseases through network biology JA Santiago, V Bottero, JA Potashkin Frontiers in aging neuroscience 9, 166, 2017 | 74 | 2017 |
| Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients JA Potashkin, JA Santiago, BM Ravina, A Watts, AA Leontovich Public Library of Science 7 (8), e43595, 2012 | 74 | 2012 |
| A network approach to clinical intervention in neurodegenerative diseases JA Santiago, JA Potashkin Trends in molecular medicine 20 (12), 694-703, 2014 | 69 | 2014 |
| Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson’s disease patients JA Santiago, JA Potashkin PLoS One 10 (11), e0142582, 2015 | 40 | 2015 |
| Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease JA Santiago, CR Scherzer, JA Potashkin PLoS One 9 (10), e109042, 2014 | 40 | 2014 |
| Blood transcriptomic meta-analysis identifies dysregulation of hemoglobin and iron metabolism in Parkinson’disease JA Santiago, JA Potashkin Frontiers in Aging Neuroscience 9, 73, 2017 | 38 | 2017 |
| Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease JA Santiago, AM Littlefield, JA Potashkin Scientific Reports 6 (1), 34579, 2016 | 37 | 2016 |
| Transcriptomic and network analysis highlight the association of diabetes at different stages of Alzheimer’s disease JA Santiago, V Bottero, JA Potashkin Frontiers in Neuroscience 13, 498466, 2019 | 34 | 2019 |
| Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer’s patients JA Potashkin, V Bottero, JA Santiago, JP Quinn PLoS One 14 (9), e0222921, 2019 | 26 | 2019 |
| Specific splice variants are associated with Parkinson's disease JA Santiago, CR Scherzer, Harvard Biomarker Study, JA Potashkin Movement disorders 28 (12), 1724-1727, 2013 | 25 | 2013 |
| Evaluation of RNA blood biomarkers in the Parkinson’s disease biomarkers program JA Santiago, V Bottero, JA Potashkin Frontiers in aging neuroscience 10, 157, 2018 | 24 | 2018 |
| A network approach to diagnostic biomarkers in progressive supranuclear palsy JA Santiago, JA Potashkin Movement Disorders 29 (4), 550-555, 2014 | 23 | 2014 |
